<DOC>
	<DOCNO>NCT01455883</DOCNO>
	<brief_summary>Phase 3 study examine treatment ITCA 650 compare glimepiride add metformin monotherapy reduce HbA1c patient type 2 diabetes .</brief_summary>
	<brief_title>A Study Evaluate ITCA 650 Compared Glimepiride Treatment Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>HbA1c 7.5 % 10.5 % metformin monotherapy BMI 25 &amp; 45 kg/m2 thiazolidinedione , sulfonylurea , DPP4 , exenatide , alpha glucosidase inhibitor , meglitinides insulin within last 3 month history pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>